The company’s two-dose vaccine wasn’t expected to suddenly boost vaccination rates, and it hasn’t. Novavax’s vaccine has similar efficacy to Pfizer’s and Moderna’s options but is protein-based rather than mRNA-based, which could appeal to the 10,000 or so Americans who have chosen it since its July 19 approval.
Novavax submitted an emergency use authorization application Aug. 15 to the FDA along with data showing the third dose resulted in a “significant antibody response,” Novavax said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.